Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Syros Pharmaceuticals
(NQ:
SYRS
)
1.570
+0.040 (+2.61%)
Streaming Delayed Price
Updated: 10:07 AM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
21 Stocks Moving in Thursday's Pre-Market Session
February 03, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives sell over $20 million of 5 stocks...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 02, 2022
Gainers Syros Pharmaceuticals (NASDAQ:SYRS
Via
Benzinga
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
February 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
January 27, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 20, 2022
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 12, 2022
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...
Via
Benzinga
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
January 10, 2022
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 03, 2021
Gainers Celyad Oncology (NASDAQ:CYAD) shares rose 22.75% to $4.37 during Friday's pre-market session. The company's market cap stands at $70.3 million. Biolase (...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 03, 2021
Good morning, investor! We're at the end of the week and it starts off with the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Syros to Participate in Upcoming Investor Conferences
November 16, 2021
From
Syros Pharmaceuticals
Via
Business Wire
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 05, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Earnings Preview For Syros Pharmaceuticals
November 04, 2021
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
October 29, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Earnings Scheduled For November 5, 2021
November 05, 2021
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter. • Healthcare Trust (NYSE:HTA) is...
Via
Benzinga
Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
October 13, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
October 12, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
September 29, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
September 28, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
September 27, 2021
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 21, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...
Via
Benzinga
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
September 20, 2021
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data demonstrated...
Via
Benzinga
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
September 20, 2021
From
Syros Pharmaceuticals
Via
Business Wire
48 Biggest Movers From Friday
September 20, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6...
Via
Benzinga
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
September 13, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
September 10, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
September 09, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Looking Into Syros Pharmaceuticals's Return On Capital Employed
September 07, 2021
Benzinga Pro data, Syros Pharmaceuticals (NASDAQ:SYRS) reported Q2 sales of $5.16 million. Earnings fell to a loss of $26.14 million, resulting in a 24.85% decrease from last...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.